Trial Halted After Niacin Surpasses Ezetimibe

Rather, they said they “would support the use of niacin as the preferred adjunctive agent to be used in combination with the maximal dose of a potent statin in persons who have low levels of HDL cholesterol and established cardiovascular disease.” More clinical trials are currently underway.

Dr. Taylor reported receiving lecture fees from Abbott. Dr. Blumenthal and Dr. Michos reported no relevant conflicts of interest.

'We believe that prudent clinical practice currently favors the avoidance of ezetimibe.'

Source DR. TAYLOR